Education
About Us
Working with TipRanks
Follow Us
Evofem Biosciences (EVFM)
OTHER OTC:EVFM
EVFM Stock Chart & Stats
$0.01
>-$0.01(-8.76%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.76%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume1.62M
Average Volume (3M)589.38K
Market Cap
$1.11M
Enterprise Value$66.35M
Total Cash (Recent Filing)$578.00K
Total Debt (Recent Filing)$65.87M
Price to Earnings (P/E)3.0
Beta0.12
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding132,530,080
10 Day Avg. Volume412,838
30 Day Avg. Volume589,380
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap59.60
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit4.40
Enterprise Value/Ebitda32.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
First-year Operating ProfitAchieving operating profitability and record annual net sales signals the business can reach a self-sustaining cost/revenue profile. If driven by recurring product sales and expense discipline, this provides a durable improvement in cash flow potential and strategic optionality over the next several quarters.
Meaningful Operating Expense ReductionA structural reduction in operating costs materially lowers the firm’s breakeven, enabling smaller revenue bases to support profitability. If cost cuts reflect permanent operational efficiencies and lower manufacturing costs, they improve long-term margin sustainability and extend runway versus prior burn rates.
Regulatory & Clinical ProgressProgress on regulatory approvals and a funded Phase 4 trial strengthen market access and the clinical/economic case for Solosec. Durable gains from favorable pricing certificates and stronger evidence could expand uptake, reimbursement, and long-term revenue streams in international and STI markets.
Bears Say
Highly Stressed Balance SheetA deeply negative equity position and leverage materially constrain financial flexibility, raising refinancing and going-concern risks. This structural capital weakness limits the company's ability to fund R&D, scale commercialization, or absorb setbacks without dilutive financing or costly debt, persisting over months.
Persistent Cash BurnOngoing negative operating and free cash flows indicate the company still consumes cash despite improvement. Continued burn necessitates external financing or further cost cuts; absent reliable recurring revenues, this structural cash shortfall threatens liquidity and strategic execution over a multi-quarter horizon.
Reliance On Nonrecurring GainsProfitability improvements partly reflect one-off items rather than core operations, reducing earnings quality. Coupled with management's own note of capital constraints, reliance on nonrecurring gains undermines the durability of results and increases the risk that reported profits are not repeatable without sustained revenue growth.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $1.11M.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Apr 30, 2026 which is in 37 days.
How were Evofem Biosciences’s earnings last quarter?
Evofem Biosciences released its earnings results on Feb 26, 2026. The company reported $0.022 earnings per share for the quarter, beating the consensus estimate of N/A by $0.022.
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Evofem Biosciences reported an EPS of $0.022 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---